Roche Pharmaceutical Development and Sales Overview

Roche gRED neuroscience and infectious diseases development programs Molecule Indication Phase # of patients Neuroscience Status CT Identifier Prodromal to mild Alzheimer's disease semorinemab (RG6100)1 Mild-to-moderate Alzheimer's disease || 457 || = FPI Q4 2017 Primary endpoint not met Q3 2020 NCT03289143 (TAURIEL) Data presented at CTAD 2020 FPI Q1 2019 One of two co-primary endpoints met Q3 2021 Data presented at CTAD 2021 272 The Open Label Extension is ongoing NCT03828747 (LAURIET) Infectious Diseases LepB inhibitor (RG6319) Complicated urinary tract infection 56 FPI Q1 2022 Partner: 1AC Immune 140

View entire presentation